Bli medlem
Bli medlem

Du är här



Oslo, Norway, 22 May, 2015:
Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on
photodynamic technologies in dermatology and cancer, announces today the
appointment of Juno Pharmaceuticals as their exclusive distributor for the
registration and commercialization of Hexvix in Australia and New Zealand.
Hexvix is Photocure's flagship product to aid in the diagnosis and management
of bladder cancer.

Under the terms of the agreement, Photocure will receive €500,000 in milestone
payments for the rights to Hexvix in the territory, of which Photocure has
received €250 000.

Juno, who will fund all costs to secure regulatory approval, will begin the
filing process immediately. . During the review process, Juno Pharmaceuticals
will initiate the preparations for the launch of Hexvix in Australia and New
Zealand. The market potential in the territory is estimated to be similar to
the potential in the Nordics, where Photocure commercializes Hexvix with its
own sales team.

Kjetil Hestdal, President&CEO of Photocure, said:
"We are happy to report that Hexvix commercialization is progressing well and
we continue to expand into new territories to ensure patients and Urologists
have access to the most optimal treatment for the diagnosis and management of
bladder cancer. We are pleased to have secured Juno Pharmaceuticals as our
new distribution partner in Australia and New Zealand with their strong and
experienced team".

For further information, please contact:


President&CEO Kjetil Hestdal
Tel: + 47 913 19 535,

CFO Erik Dahl
Tel: +47 50 55 000,

About Photocure ASA

Photocure ASA, headquartered in Oslo, Norway, is a specialty pharmaceutical
company and world leader in photodynamic technology. Based on our unique
proprietary Photocure Technology®platform, Photocure develops and
commercializes highly selective and effective solutions in disease areas with
high unmet medical need, such as bladder cancer, HPV and precancerous
cervical lesions, colorectal cancer and skin conditions. Our aim is to
provide solutions that can improve health outcomes for patients worldwide.
Photocure is listed on the Oslo Stock Exchange (OSE: PHO). Information about
Photocure is available at

About Hexvix




(hexaminolevulinate hydro-chloride) is an innovative breakthrough technology
in the diagnosis and management of non-muscle-invasive bladder cancer. It is
designed to selectively target malignant cells in the bladder and induce
fluorescence during a cystoscopic procedure using a blue-light enabled
cystoscope. Using Hexvix
as an adjunct to standard white-light cystoscopy enables the urologist to
better detect and remove lesions, leading to a reduced risk of recurrence.
is approved in Europe and the USA.
About Juno Pharmaceuticals
Juno Pharmaceuticals is a privately held global health care company dedicated
to introducing a range of innovative pharmaceutical products. Juno
Pharmaceuticals was founded in 2012 by a group of experienced international
pharmaceutical executives and are a fast growing global specialty
pharmaceutical company. Our product portfolio and pipeline covers a broad
spectrum of therapeutic areas and formats including oral solid dosages,
injectable, suspensions, ophthalmic solutions, creams and patches. With a
primary focus on the hospital market channel, Juno has access to a range of
presentations across multiple therapeutic areas including biosimilar
products. An extensive global network of manufacturers allows us to source
niche, lifesaving products for our customers. Juno operates in the
Australian, Canadian, Polish and United Kingdom markets.
All trademarks mentioned in this release are protected by law and are
registered trademarks of Photocure ASA.
This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Photocure ASA via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.